USPTO serial 79348442
BI-CYGNI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 19, 2023
- Examiner
- KOVALSKY, LAURA G
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BI-CYGNI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leon R. Legleiter
Leon R. Legleiter KDW Firm PLLC2601 Weston Parkway, Suite 103Cary, NC 27513UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Antibodies for medical purposes; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-infective antibiotics; anti-infective preparations; anti-infectives; anti-inflammatories; antiparasitic preparations; anti-viral agents; biological adjuvants for medical purposes; biological preparations for medical purposes, namely for the treatment of cancer; biological preparations for the treatment of cancer; biological preparations for veterinary purposes; biological diagnostic reagents for medical use; biological diagnostic reagents for veterinary use; biological tissue cultures for medical purposes; biopharmaceutical preparations for the treatment of cancer; biotechnological preparations for medical use for the treatment of cancer; blood components in the nature of blood protein fractions, blood cellular fractions, blood plasma and cord blood for medical purposes; cardiovascular pharmaceutical preparations; cardiovascular preparations; cells for medical use; cellular function activating agents for medical purposes; chemical adjuvants for medical purposes; chemical preparations for medical purposes, namely for prevention or treatment of cancer; chemical preparations for pesticidal purposes, namely, pesticides; chemical preparations for pharmaceutical purposes namely for prevention or treatment of cancer; chemical preparations for testing blood for medical purposes; chemical reagents for medical use; chemical preparations for pharmaceutical use, namely for prevention or treatment of cancer; chemotherapeutics; clinical diagnostic reagents for medical use; clinical medical reagents; pharmaceutical compounds for treating cancer; pharmaceutical compounds for treating correlated pulmonary syndromes; pharmaceutical compounds for treating respiratory diseases; cord blood for medical purposes; culture media for use in treatment of cancer for medical use; cultures of microorganisms and mammalian cultures for medical use; cytostatic drugs for medical purposes; cytostatics for medical purposes; cytostatics for pharmaceutical purposes; diagnostic agents for medical use; diagnostic agents for pharmaceutical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; diagnostic preparations for medical use; diagnostic preparations and materials in the nature of cancer diagnostics for medical purposes; diagnostic preparations for medical and veterinary use; diagnostic preparations for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic reagents for medical use; diagnostic reagents for medicinal use; diagnostic substances for medical use; diagnostic testing materials in the natural of cancer diagnostics for medical use; drugs for medical purposes, namely cancer treatment; haemostatic preparations in the nature of medical haemostatic paste, haemostatic pencils; homeopathic medicines in the nature of pharmaceuticals for use in the treatment of cancer; immunomodulators; immunostimulants; immunosuppressants for use following transplantation in the case of graft rejection; immunotherapeutic agents for bacterial infections; in vitro diagnostic preparations for medical use; living cells for medical use; living cells for veterinary use; medicines, namely, medicines for cancer disorders; medicines for human purposes, namely, cancer medicines; medicines for intestinal disorders; medicines for the treatment of gastrointestinal diseases; medicines for treating intestinal disorders; pain relief preparations in the nature of pain relief medication; pharmaceutical compositions, namely, preparations for the treatment of cancer; pharmaceutical drugs, namely, preparations for the treatment of cancer; pharmaceutical preparations, namely, preparations for the treatment of cancer; pharmaceutical preparations and substances, namely, preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for use in gynecology; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in the field of anesthesia; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances with anti-inflammatory properties; pharmaceutical preparations and substances with antipyretic properties; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for human use, namely, preparations for the treatment of cancer; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for medical purposes, namely, preparations for the treatment of cancer; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the prevention of allergies; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for the prevention of diseases of the cardio-vascular system; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the prevention of diseases of the genitourinary system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for the prevention of diseases of the metabolic system; pharmaceutical preparations for the prevention of diseases of the musculo-skeletal system; pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the prevention of disorders caused by bacteria; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the prevention of disorders of the endocrine system; pharmaceutical preparations for the prevention of disorders of the genitourinary system; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for the prevention of disorders of the musculo-skeletal system; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of disorders of the respiratory system; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the prevention of ocular diseases; pharmaceutical preparations for the prevention of ocular disorders; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of diseases caused by bacteria; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the genitourinary system; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of diseases of the musculo-skeletal system; pharmaceutical preparations for the treatment of disorders caused by bacteria; pharmaceutical preparations for the treatment of disorders of the endocrine system; pharmaceutical preparations for the treatment of disorders of the genitourinary system; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of esophagitis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for treating allergic rhinitis; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating digestive system disorders; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparations for treating gastrointestinal disorders; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for treating rheumatological diseases; pharmaceutical preparations for treating sensory organ disorders; pharmaceutical preparations for treating skeletal diseases; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for treating the symptoms of radiation sickness; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for use in urology; pharmaceutical preparations for veterinary use for the prevention and treatment of cancer; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for treating respiratory diseases; pharmaceuticals and natural remedies for the prevention and treatment of cancer; pharmacological preparations for skin care; preparations for the treatment of asthma; radioactive substances for medical purposes; radio-isotope markers for therapeutic or diagnostic use; radiological contrast substances for medical purposes; radiopharmaceutical products, namely, pharmaceutical products for the prevention and treatment of cancer; clinical medical reagents for analytical purposes; clinical reagents for veterinary or medicalanalytical purposes; clinical medical reagents for in-vitro laboratory use; clinical veterinary reagents for in-vitro laboratory use; clinical reagents for medical use; clinical medical reagents for use in diagnostic tests; clinical veterinary reagents for use in diagnostic tests; reconstituted cells for clinical treatments for skin care; reconstituted cells for medical treatments for skin care; tissue-regenerative pharmaceutical preparations; tissues for medical use in the nature of biological tissue grafts and human allograft tissue | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 23, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 28, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 28, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 19, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 19, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 19, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 4, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 3, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 3, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 13, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 13, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 13, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 25, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 25, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 25, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 25, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 25, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 8, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 7, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 7, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 28, 2023 | RFNP | REFUSAL PROCESSED BY IB | — |
| Feb 8, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 7, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 13, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 12, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 6, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 6, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 2, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 1, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |